This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Semaglutide (2.4 mg once weekly) resulted in significant weight loss and improved cardiometabolic factors compared to placebo.
Why it matters
With obesity being a major health issue, effective treatments like semaglutide can help manage weight and reduce related health risks. Understanding its safety profile is crucial for healthcare providers.
How the study worked
The STEP program included phase 3 trials comparing semaglutide to placebo in adults with obesity, focusing on weight loss and safety.
What this study cannot tell us
The study primarily focused on short-term outcomes, and long-term effects of semaglutide are still being evaluated.
Read the original research
Efficacy and safety of semaglutide for weight management: evidence from the STEP program.
Postgraduate medicine, 134(sup1), 5-17
Citation
Amaro, Anastassia; Sugimoto, Danny; Wharton, Sean. (2022). Efficacy and safety of semaglutide for weight management: evidence from the STEP program.. Postgraduate medicine, 134(sup1), 5-17. https://doi.org/10.1080/00325481.2022.2147326